Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Anagenics ( (AU:AN1) ).
Anagenics Limited has announced the termination of its Licence Agreement with Lyramid Pty Ltd, now owned by Roquefort Therapeutics, regarding its Midkine intellectual property portfolio. This termination, effective from 2 November 2025, allows Anagenics to regain control over its Midkine products and intellectual property, enabling the company to further commercialize this product range independently. The extension of the transaction deadline between Roquefort Therapeutics and Pleiades Pharma Limited to 31 January 2026 does not affect Anagenics’ decision to terminate the agreement, potentially impacting its strategic positioning and operations in the market.
More about Anagenics
Anagenics Limited is a health, beauty, and wellness company that enhances shareholder value through the global distribution and sales of its proprietary and licensed brands. The company specializes in differentiated, clinically validated anti-aging solutions, with its subsidiary BLC Cosmetics Pty Ltd focusing on the sales and distribution of leading Australian and international cosmetic and wellness products.
Current Market Cap: A$2.48M
For detailed information about AN1 stock, go to TipRanks’ Stock Analysis page.